← Evidence map

ArticleInvestigational new drugs2026

Class-level DILI saturation and hERG-driven risk stratification among 2024-2025 FDA-approved kinase inhibitors: an in silico multi-platform safety analysis.

Nihan Küçük Yılmaz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Class-level DILI saturation and hERG-driven risk stratification among 2024-2025 FDA-approved kinase inhibitors: an in silico multi-platform safety analysis. | OpenQuestion